Clinical Trial Update: HAIC Combined With Anlotinib and TQB2450 as Adjuvant Therapy in HCC Patients With High Risk of Recurrence After Resection [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating HAIC combined with Anlotinib and TQB2450 as adjuvant therapy for hepatocellular carcinoma patients at high risk of recurrence …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Anlotinib (anlotinib)
• HAIC (hepatic artery infusion chemotherapy)
• TQB2450

Snippet

Sponsor: Fudan University | Conditions: Hepatocarcinoma | Phase 2 | Status: UNKNOWN